Treatment Options After Skyrizi Failure in Ulcerative Colitis
After failing risankizumab (Skyrizi) for ulcerative colitis, switch to upadacitinib as the most effective option, particularly if you have failed multiple biologics, or consider infliximab, vedolizumab, or other TNF antagonists if biologic-naïve prior to Skyrizi. 1, 2
Primary Recommendation: Upadacitinib
The 2024 AGA guidelines and comparative efficacy data demonstrate that upadacitinib shows superior efficacy in biologic-exposed patients, even when 30-35% had failed two prior biologics 2. This makes it the strongest choice after Skyrizi failure, as risankizumab is an IL-23 inhibitor and switching mechanism of action is critical.
Important FDA consideration: JAK inhibitors like upadacitinib are FDA-labeled for use after TNF antagonist failure or intolerance 1. However, since you've already failed an IL-23 inhibitor (Skyrizi), this represents advanced therapy failure and upadacitinib remains appropriate.
Alternative Strong Options
If Biologic-Naïve Before Skyrizi:
- Infliximab (superior to adalimumab in comparative studies) 2
- Vedolizumab (anti-integrin, different mechanism)
- Golimumab (TNF antagonist)
All three received strong recommendations from the 2024 AGA guidelines 1.
If Multiple Biologic Failures:
The efficacy hierarchy changes dramatically with prior exposures:
- Upadacitinib remains most effective even after multiple biologic failures 2
- Avoid ozanimod - it loses efficacy dramatically in biologic-exposed patients (4% vs 3% placebo in those with 2 prior biologics) 2
Other Reasonable Options
Based on 2024 AGA strong recommendations 1:
- Tofacitinib (JAK inhibitor, though less effective than upadacitinib)
- Guselkumab (another IL-23 inhibitor, but switching within same class less ideal)
- Etrasimod (S1P receptor modulator)
Critical Safety Monitoring
Since you're switching from Skyrizi, be aware:
For JAK inhibitors (upadacitinib, tofacitinib):
- Screen for cardiovascular risk factors (age ≥65, smoking history, prior CV disease)
- Consider thromboembolism risk
- FDA boxed warnings exist, though IBD-specific data show comparable safety to TNF antagonists 1
For any new biologic:
- Screen for tuberculosis before initiation
- Ensure age-appropriate vaccinations are complete (avoid live vaccines during treatment) 3
- Monitor for infections
Combination Therapy Consideration
If switching to a TNF antagonist (infliximab, adalimumab, golimumab), the AGA conditionally recommends combining with an immunomodulator (thiopurine) rather than monotherapy 1. This does not apply to non-TNF biologics or JAK inhibitors where evidence is insufficient.
Extended Induction Strategy
If you choose to give Skyrizi another chance (though not recommended as primary approach), extended induction beyond 12 weeks can salvage some initial non-responders - over 50% achieved clinical response with extended treatment to 24 weeks 4. However, switching mechanism of action is generally preferred over extending a failed therapy.